Biogen Inc. (NASDAQ:BIIB) Forecasted to Earn FY2027 Earnings of $15.76 Per Share

Biogen Inc. (NASDAQ:BIIBGet Rating) – Investment analysts at Wedbush issued their FY2027 earnings per share (EPS) estimates for shares of Biogen in a research report issued on Monday, January 23rd. Wedbush analyst L. Chico anticipates that the biotechnology company will earn $15.76 per share for the year. Wedbush has a “Neutral” rating and a $247.00 price target on the stock. The consensus estimate for Biogen’s current full-year earnings is $17.03 per share.

Biogen (NASDAQ:BIIBGet Rating) last announced its earnings results on Tuesday, October 25th. The biotechnology company reported $4.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.13 by $0.64. Biogen had a return on equity of 21.31% and a net margin of 27.64%. The company had revenue of $2.51 billion for the quarter, compared to analyst estimates of $2.47 billion. During the same period in the prior year, the company posted $4.77 EPS. The firm’s quarterly revenue was down 9.7% compared to the same quarter last year.

BIIB has been the topic of several other research reports. Barclays boosted their price target on Biogen from $275.00 to $313.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 30th. The Goldman Sachs Group reiterated a “buy” rating and set a $370.00 price target on shares of Biogen in a research note on Thursday, December 1st. Jefferies Financial Group boosted their price target on Biogen from $325.00 to $350.00 and gave the company a “buy” rating in a research note on Wednesday, November 30th. StockNews.com assumed coverage on Biogen in a research note on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Finally, Guggenheim boosted their price target on Biogen from $265.00 to $270.00 and gave the company a “neutral” rating in a research note on Friday, November 11th. Eight investment analysts have rated the stock with a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Biogen has a consensus rating of “Moderate Buy” and an average target price of $306.46.

Biogen Trading Down 0.0 %

Shares of NASDAQ:BIIB opened at $291.88 on Wednesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.49 and a quick ratio of 2.14. The business’s 50-day moving average is $288.07 and its 200 day moving average is $252.73. The firm has a market capitalization of $42.03 billion, a P/E ratio of 14.86, a P/E/G ratio of 1.84 and a beta of 0.23. Biogen has a 1 year low of $187.16 and a 1 year high of $311.88.

Insider Buying and Selling at Biogen

In other Biogen news, EVP Susan H. Alexander sold 5,532 shares of the stock in a transaction that occurred on Thursday, October 27th. The stock was sold at an average price of $280.70, for a total transaction of $1,552,832.40. Following the completion of the transaction, the executive vice president now owns 39,396 shares of the company’s stock, valued at $11,058,457.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Biogen news, EVP Susan H. Alexander sold 5,532 shares of the stock in a transaction that occurred on Thursday, October 27th. The stock was sold at an average price of $280.70, for a total transaction of $1,552,832.40. Following the completion of the transaction, the executive vice president now owns 39,396 shares of the company’s stock, valued at $11,058,457.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Ginger Gregory sold 5,610 shares of the stock in a transaction that occurred on Monday, November 14th. The shares were sold at an average price of $300.11, for a total value of $1,683,617.10. Following the transaction, the executive vice president now directly owns 5,711 shares of the company’s stock, valued at approximately $1,713,928.21. The disclosure for this sale can be found here. Insiders own 0.65% of the company’s stock.

Hedge Funds Weigh In On Biogen

Hedge funds have recently made changes to their positions in the company. Larson Financial Group LLC acquired a new stake in shares of Biogen in the third quarter valued at approximately $25,000. FNY Investment Advisers LLC increased its holdings in shares of Biogen by 526.7% in the third quarter. FNY Investment Advisers LLC now owns 94 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 79 shares during the last quarter. MinichMacGregor Wealth Management LLC acquired a new stake in shares of Biogen in the fourth quarter valued at approximately $28,000. CVA Family Office LLC increased its holdings in shares of Biogen by 50.0% in the third quarter. CVA Family Office LLC now owns 105 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 35 shares during the last quarter. Finally, Trustcore Financial Services LLC increased its holdings in shares of Biogen by 564.7% in the third quarter. Trustcore Financial Services LLC now owns 113 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 96 shares during the last quarter. Institutional investors and hedge funds own 84.40% of the company’s stock.

Biogen Company Profile

(Get Rating)

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.

Featured Stories

Earnings History and Estimates for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.